144 related articles for article (PubMed ID: 18775581)
1. Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone.
Monami M; Marchionni N; Mannucci E
Diabetes Res Clin Pract; 2008 Oct; 82(1):48-57. PubMed ID: 18775581
[TBL] [Abstract][Full Text] [Related]
2. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Nissen SE; Wolski K
Arch Intern Med; 2010 Jul; 170(14):1191-1201. PubMed ID: 20656674
[TBL] [Abstract][Full Text] [Related]
4. [Therapy with glitazones--a risk for cardiovascular disease?].
Rottlaender D; Michels G; Erdmann E; Hoppe UC
Dtsch Med Wochenschr; 2007 Dec; 132(49):2629-32. PubMed ID: 18050028
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Nissen SE; Wolski K
N Engl J Med; 2007 Jun; 356(24):2457-71. PubMed ID: 17517853
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
Boyle P
South Med J; 2007 Nov; 100(11):1063-4. PubMed ID: 17984728
[No Abstract] [Full Text] [Related]
7. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
[TBL] [Abstract][Full Text] [Related]
8. The safety of rosiglitazone in the treatment of type 2 diabetes.
Singh S; Loke YK
Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
Chiquette E; Ramirez G; Defronzo R
Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
[TBL] [Abstract][Full Text] [Related]
10. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
12. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
14. The Avandia debacle: methodology and practical importance of the findings.
Meneghini LF; Florez H; Tamariz L
South Med J; 2007 Nov; 100(11):1062-3. PubMed ID: 17984727
[No Abstract] [Full Text] [Related]
15. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
McGuire DK
Diab Vasc Dis Res; 2007 Jun; 4(2):77-9. PubMed ID: 17654438
[No Abstract] [Full Text] [Related]
16. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
Derosa G; Gaddi AV; Piccinni MN; Salvadeo S; Ciccarelli L; Fogari E; Ghelfi M; Ferrari I; Cicero AF
Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone and cardiovascular risk.
Kaul S; Diamond GA
Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
[TBL] [Abstract][Full Text] [Related]
19. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
Jain R; Mullins CD; Lee H; Wong W
Res Social Adm Pharm; 2012; 8(1):47-59. PubMed ID: 21733760
[TBL] [Abstract][Full Text] [Related]
20. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Olansky L; Marchetti A; Lau H
Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
